BioCentury | Jun 16, 2014
Company News

Enterome Bioscience, Synthetic Biologics deal

...and to start a Phase II trial in 1H15. Synthetic Biologics acquired the product from Prev AbR LLC...
BioCentury | Dec 10, 2012
Company News

Prev AbR, Synthetic Biologics deal

...based on Synthetic close of $1.92 prior to the deal close (see BioCentury, Nov. 19). Prev AbR LLC...
BioCentury | Nov 19, 2012
Company News

Prev AbR LLC, Synthetic Biologics deal

...an IND for SYN-004 based on the compounds' structural similarities. P1A completed Phase II testing. Prev AbR LLC...
Items per page:
1 - 3 of 3
BioCentury | Jun 16, 2014
Company News

Enterome Bioscience, Synthetic Biologics deal

...and to start a Phase II trial in 1H15. Synthetic Biologics acquired the product from Prev AbR LLC...
BioCentury | Dec 10, 2012
Company News

Prev AbR, Synthetic Biologics deal

...based on Synthetic close of $1.92 prior to the deal close (see BioCentury, Nov. 19). Prev AbR LLC...
BioCentury | Nov 19, 2012
Company News

Prev AbR LLC, Synthetic Biologics deal

...an IND for SYN-004 based on the compounds' structural similarities. P1A completed Phase II testing. Prev AbR LLC...
Items per page:
1 - 3 of 3